Daclatasvir and Sofosbuvir Therapy Enhance Monocyte Phenotypic Changes in Naive Chronic Hepatitis C Patients: A Prospective Cohort Study.
Hanan Mahmoud FayedAli A GhweilMona M AbdelMeguidPublished in: Interdisciplinary perspectives on infectious diseases (2019)
CHC infection promotes a proinflammatory and profibrotic monocytes profile. SOF/DCV therapy efficiently decreases viral load, reduces fibrosis potentials, attenuates monocyte activation, normalizes monocytes phenotypic abnormalities, and modulates monocyte subsets recruitment and differentiation later in the liver.
Keyphrases
- dendritic cells
- peripheral blood
- hepatitis c virus
- end stage renal disease
- endothelial cells
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- hiv infected
- hepatitis c virus infection
- liver fibrosis
- patient reported outcomes
- combination therapy
- mesenchymal stem cells
- cell therapy
- antiretroviral therapy